JV
Therapeutic Areas
BeOne Medicines Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BRUKINSA (zanubrutinib) | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Approved |
| TEVIMBRA (tislelizumab) | Various Solid Tumors | Approved / Phase 3 |
| BCL2 Inhibitor | B-Cell Malignancies (e.g., CLL/SLL) | Late-Stage (Phase 3) |
| CDAC Platform Asset(s) | Undisclosed B-Cell Malignancies | Discovery / Preclinical / Early Clinical |